EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors

Prostate

Volumn 73, Issue 13, 2013, Pages 1453-1461

  Ren, Jiangong ^a   Bollu, Lakshmi R ^a   Su, Fei ^a   Gao, Guang ^a   Xu, Lei ^a   Huang, Wei Chien ^b,c   Hung, Mien Chie ^b,c,d   Weihua, Zhang ^a  

^a University of Houston   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

cancer; EGFR; glucose; prostate; SGLT1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PHLORIZIN; PROTEASOME; PROTEIN TYROSINE KINASE INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 1;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

CANCER; EGFR; GLUCOSE; PROSTATE; SGLT1;

CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; HUMANS; MALE; PHOSPHORYLATION; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SODIUM-GLUCOSE TRANSPORTER 1;

EID: 84882247018     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22692     Document Type: Article

References (31)

1. Hynes NE, Lane HA,. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5 (5): 341-354.
2. Weiss J,. First line erlotinib for NSCLC patients not selected by EGFR mutation: Keep carrying the TORCH or time to let the flame die ? Transl Lung Cancer Res 2012; 1 (3): 219-223.
3. Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ,. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003; 21 (7): 1301-1306.
4. Dancey JE, Freidlin B,. Targeting epidermal growth factor receptor-Are we missing the mark ? Lancet 2003; 362 (9377): 62-64.
5. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM,. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004; 90 (2): 449-454.
6. Pu YS, Hsieh MW, Wang CW, Liu GY, Huang CY, Lin CC, Guan JY, Lin SR, Hour TC,. Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells. Biochem Pharmacol 2006; 71 (6): 751-760.
7. Sherwood ER, Lee C,. Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 1995; 13 (5): 290-296.
8. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L,. Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 2005; 113 (4): 619-628.
9. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L,. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005; 23 (3): 455-460.
10. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB,. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007; 7: 142.
11. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, LaMantia C, Mourton T, Herrup K, Harris RC, Barnard JA, Yuspa SH, Coffey RT, Magnuson T,. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype. Science 1995; 269 (5221): 230-234.
12. Luetteke NC, Phillips HK, Qiu TH, Copeland NG, Earp HS, Jenkins NA, Lee DC,. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev 1994; 8 (4): 399-413.
13. Ewald JA, Wilkinson JC, Guyer CA, Staros JV,. Ligand- and kinase activity-independent cell survival mediated by the epidermal growth factor receptor expressed in 32D cells. Exp Cell Res 2003; 282 (2): 121-131.
14. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC,. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008; 13 (5): 385-393.
15. Wright EM, Loo DD, Hirayama BA,. Biology of human sodium glucose transporters. Physiol Rev 2011; 91 (2): 733-794.
16. Castaneda-Sceppa C, Castaneda F,. Sodium-dependent glucose transporter protein as a potential therapeutic target for improving glycemic control in diabetes. Nutr Rev 2011; 69 (12): 720-729.
17. Hanahan D, Weinberg RA,. Hallmarks of cancer: The next generation. Cell 2011; 144 (5): 646-674.
18. Ganapathy V, Thangaraju M, Prasad PD,. Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond. Pharmacol Ther 2009; 121 (1): 29-40.
19. Lai B, Xiao Y, Pu H, Cao Q, Jing H, Liu X,. Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma. Arch Gynecol Obstet 2012; 285 (5): 1455-1461.
20. Hanabata Y, Nakajima Y, Morita K, Kayamori K, Omura K,. Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinoma. Odontology 2012; 100 (2): 156-163.
21. Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ, Xia LP, Jiang WQ, Hu PL, Chen XX, Zhou FF, Wang F,. Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol 2011; 28 (Suppl. 1): S197-S203.
22. Casneuf VF, Fonteyne P, Van Damme N, Demetter P, Pauwels P, de Hemptinne B, De Vos M, Van de Wiele C, Peeters M,. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest 2008; 26 (8): 852-859.
23. Blessing A, Xu L, Gao G, Bollu RL, Ren J, Li H, Wu X, Su F, Huang W-C, Hung MC, Huo L, Palapattu SG, Weihua Z,. Sodium/glucose co-transporter 1 expression increases in human diseased prostate. J Cancer Sci Ther 2012; 4 (9): 306-312.
24. Lee ST, Lawrentschuk N, Scott AM,. PET in prostate and bladder tumors. Semin Nucl Med 2012; 42 (4): 231-246.
25. Oyama N, Akino H, Suzuki Y, Kanamaru H, Sadato N, Yonekura Y, Okada K,. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999; 29 (12): 623-629.
26. Han L, Ma Q, Li J, Liu H, Li W, Ma G, Xu Q, Zhou S, Wu E,. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR. PLoS ONE 2011; 6 (11): e27074.
27. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J,. Phlorizin: A review. Diabetes Metab Res Rev 2005; 21 (1): 31-38.
28. Bazley LA, Gullick WJ,. The epidermal growth factor receptor family. Endocr Relat Cancer 2005; 12 (Suppl. 1): S17-S27.
29. Xu S, Weihua Z,. Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin. Prostate 2011; 71: 1216-1224.
30. Ikari A, Nagatani Y, Tsukimoto M, Harada H, Miwa M, Takagi K,. Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cells. Biochim Biophys Acta 2005; 1717 (2): 109-117.
31. Yu LC, Huang CY, Kuo WT, Sayer H, Turner JR, Buret AG,. SGLT-1-mediated glucose uptake protects human intestinal epithelial cells against Giardia duodenalis-induced apoptosis. Int J Parasitol 2008; 38 (8-9): 923-934.